Advisory board · Dr. Farah Kimura

05 Jan 2026 · Phone · Dr. Farah Kimura, Memorial Sloan Kettering · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0076—

Capture insight from this engagement

Location: Memorial Sloan Kettering
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Duration of response
Comparator checkpoint monotherapy

Scientific content used

VTX core scientific deck v3.2

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Advisory board with thoracic medical oncologist at Memorial Sloan Kettering. Discussed sequencing after progression, duration of response, comparator checkpoint monotherapy.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0076

Audit history (0)

All create, update and approval events for this record

No audit events in sample data